Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12782MR)

This product GTTS-WQ12782MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12782MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8011MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ3205MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ15222MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ14719MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ12591MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ15041MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ8679MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ15139MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYNT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW